MiniMed shares fell 2.4% to $23.27 at the latest close. The backdrop is a filing that appears, at first glance, to show a business crossing a line: revenue rose 6.7% to $843 million, gross margin jumped to 55.2%, and operating income moved from a $100 million loss to $5 million.
Then the cash-flow statement presents a different view of the turnaround. Operating cash flow worsened from negative $27 million to negative $49 million, even as cash on the balance sheet rose from $10 million to $207 million. The increase in cash is visible; its operating source is not.
The balance-sheet changes help explain why those figures can coexist. Accounts receivable fell 72.4% to $180 million, inventory declined 12.7% to $356 million, and capital spending dropped 75.4% to $41 million. Those are substantial movements, but the company does not disclose a single cause for the negative operating cash flow in the supplied filing receipts.
Management says the sales increase came mainly from more units sold, with an extra week also helping the comparison.
"International sales increased by 18% and U.S. sales increased 13% primarily as a result of increased volumes, as well as the benefit of the additional week of sales in the current-year period as compared to the prior year period."
10-Q 2026-09-08; revenue
That gives the revenue line a concrete operating explanation. It also puts the margin improvement in sharper relief: gross profit rose 28.5%, far faster than sales, while operating expenses included $19 million of additional commercialization activity and $10 million more in information technology and software development costs.
"The increase was primarily driven by $19 million of incremental commercialization activities to support higher sales of the Company in the current year, as well as a $10 million increase in information technology and software development costs."
10-Q 2026-09-08; revenue
MiniMed reached break-even net income, but not positive operating cash flow. The filing therefore shifts the useful question from whether the income statement improved to how much of that improvement is making its way through the business after investment and working-capital movements.
The share count adds another layer. Diluted shares rose 11.1% to 281 million from 252.8 million in the comparable three months. Earnings per share moved from negative $0.47 to $0.00, while the denominator expanded at the same time, so the EPS result also reflects the higher share count.
There is also a product-mix issue sitting behind the margin line. MiniMed says the higher mix of Simplera sensors currently carries a lower gross margin than its legacy and Instinct sensors. That exposure matters because the latest period produced a higher consolidated margin despite the disclosed lower-margin product mix, leaving the next filing to explain whether the mix, pricing, or another factor is doing the work.
MiniMed's annual results show revenue rising from 2.5B in 2024 to 3.1B in 2026, while annual net margin declined to -10.7% in the latest year. The latest three-month result is a sharper turn than that annual record, but it has not yet reached the cash-flow line.
The cleanest number to compare in MiniMed's next quarterly report is operating cash flow, starting from negative $49 million in the latest three-month period.
Source: MiniMed Group's 10-Q filed September 8, 2026, for the three months ended July 31, 2026.